SMMT250502C39000
- 0.08
- 0.000.00%
Summit Therapeutics Newsroom
Truist Financial Maintains Summit Therapeutics(SMMT.US) With Buy Rating
Summit Therapeutics (SMMT) Receives a Buy From Truist Financial
Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), Alkermes (ALKS) and Summit Therapeutics (SMMT)
Jefferies Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $44
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $44
Cantor Fitzgerald Maintains Summit Therapeutics(SMMT.US) With Buy Rating
Summit Therapeutics Analyst Ratings
Goldman Sachs Maintains Buy on Summit Therapeutics, Raises Price Target to $41
A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $30 to $44
Analysts Are Bullish on These Healthcare Stocks: Summit Therapeutics (SMMT), Altimmune (ALT)
Summit Therapeutics Price Target Maintained With a $40.00/Share by JMP Securities
Truist Financial Sticks to Their Buy Rating for Summit Therapeutics (SMMT)
Jefferies Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $44
Summit Therapeutics Is Maintained at Buy by Jefferies
Summit Therapeutics Price Target Raised to $44.00/Share From $31.00 by Jefferies
Summit Therapeutics Analyst Ratings
Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $44
Mitchell Kapoor Reaffirms Buy Rating for Summit Therapeutics Amid Promising Ivonescimab Trial Results
Truist Financial Maintains Summit Therapeutics(SMMT.US) With Buy Rating